Navigation Links
Lancing tumours into the body

ody, Ishiyama says the devices could carry drugs to the sites of infection. His latest prototype is even armed with a tiny metal spike that heats up when you apply a second magnetic field vibrating at 100 kHz.

The hot spike could be useful for destroying cancerous tissue, Ishiyama believes. The high frequency field used to heat the metal tip doesn’t interfere with steering the device, he adds.Says Edwin Jager at Linkoping University in Sweden, who is designing tiny robots to manipulate single cells in the body that “surgeons are understandably cautious about the idea of microbots floating free in the body.

If one blocked a blood vessel,” for example, it could be disastrous.He also says that Ishiyama’s prototypes might be too long to safely navigate some of the tighter turns in blood vessels.While Ishiyama concedes that his swimming machines won’t replace standard tools such as catheters for medical operations any time soon, he thinks that nanobots even smaller than this could have a distinct advantage.

'"/>




Page: 1 2

Related medicine news :

1. Multi billion-dollar suit filed against cell phone firm for causing brain tumours
2. Low-radiation treatment for brain tumours
3. Avastin under trial to test efficacy for pancreatic tumours!
4. Awake Surgery to treat Brain tumours
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Lancing tumours into the body

(Date:10/8/2008)... Dr. Paul Parker is pleased to announce enha...computer imaging for http://www.parkercenter.net/...oplasty in New Jersey]. Paramus plastic surgeon, ...raw attention to itself but rather complement othe...ll appearance, gender and ethnicity." , ...
(Date:10/8/2008)... Gastorenterologist Dr. Patricia Raymond off... East Longmeadow, MA (PRWEB) Octob...sary. In fact, the average person passes gas about...three liters daily). However, every body behaves d...s. If you are one of those unlucky few, follow the...
(Date:10/8/2008)... AccurateAnswers™ support program prov...r http://www.appointment-plus.com [online schedu... Scottsdale, AZ (PRWEB) October 8, 2008 -- Appoi...duling software, continues to expand its software ...t "software as a service" providers are ...
(Date:10/7/2008)... Merck KGaA (EMD in North America) announced...iance with Nano-Terra, Inc., a leading nanotechnol... DARMSTADT, Germany (Business Wire EON) Octob...companies, announced in February 2007, was to deve...solutions based on Merck,s materials. , , , After ...
Breaking Medicine News(10 mins):Health News:New Jersey Rhinoplasty Patients Can Now See the Future at The Parker Center for Plastic Surgery New Jersey 2Health News:New Jersey Rhinoplasty Patients Can Now See the Future at The Parker Center for Plastic Surgery New Jersey 3Health News:New Jersey Rhinoplasty Patients Can Now See the Future at The Parker Center for Plastic Surgery New Jersey 4Health News:Managing Gas Isn't Rocket Science 2Health News:Managing Gas Isn't Rocket Science 3Health News:Appointment-Plus Continues Innovation With Technical Support Program 2Health News: Merck KGaA and Nano-Terra Announce Extension of Nanotechnology Solutions Alliance 2Health News: Merck KGaA and Nano-Terra Announce Extension of Nanotechnology Solutions Alliance 3
...are commonly used for a number of painful complai... attack and stroke//. This has lead to an order by...rugs will have to carry a warning along with the i...turers. Doctors are being informed of the small ...
...nt study, women with a twin are at upto 5 times hi...an those without one//. The study was conducted o... The risk of premature ovarian failure (POF) at th...s than women from the general population. POF caus...
...lie Minogue with breast cancer has led to confusio...o get breast cancer//. Cancer Research UK said t...re likely to strike the under-70s than women over ...en revealed that 77 per cent of them thought that ...
...safe for administration in babies and toddlers, re...of flu shots//. Two flu seasons back, the federal...the age 6 months to 2 years and their family membe...ise in the number of children getting vaccinated. ...
Other Medicine News:
(Date:10/7/2008)... VIENNA, Va., Oct. 7 /...y that it has entered into a Material Transfer,Agr...h Clinical Center,(NIHCC) and the laboratory of Dr... molecular basis of changes to the tumor microenvi... Dr. Marincola is the Chief of,the Infectious Dise...
(Date:10/7/2008)... - Data Presented Today at ACG Annual Sc...wire-FirstCall/ -- Ironwood,Pharmaceuticals, Inc. ...,Inc. (NYSE: FRX ) today announced the presentati...clotide,s safety and efficacy in 420 patients with...). Analysis of the data,indicates that once- daily...
(Date:10/7/2008)... Several abstracts highlighting CIMZIA,s long...hn,s disease patients presented at American Colleg... /- Data from two studies,p...of Gastroenterology,(ACG) Annual Meeting demonstra...PEGylated anti-TNF alpha (Tumor Necrosis Factor al...
(Date:10/7/2008)... - Planned 15 Patient Cohort Enrolled in Stage A...ombination With Carboplatin and Paclitaxel -, TUS...grine,Pharmaceuticals, Inc. (Nasdaq: PPHM ), a cl...monoclonal antibodies for the treatment of cancer ...nced that it has completed,enrollment in the first...
Breaking Medicine Technology:CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect 2CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect 3Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 2Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 3Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 4Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 5CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 2CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 3CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 4CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 5CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 6CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 7CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 8CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 9Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 2Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 3Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 4Doctors See How Cancer Drug Can Damage Kidneys 14210 1Doctors See How Cancer Drug Can Damage Kidneys 14210 2Doctors See How Cancer Drug Can Damage Kidneys 14210 3New Tools Boost Alzheimers Awareness 14206 1New Tools Boost Alzheimers Awareness 14206 2New Tools Boost Alzheimers Awareness 14206 3WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 1WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 2WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 3WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 4WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 5WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 6WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 7WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 8WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 9WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 10WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 11WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 12The Makers of Conquer HA 28TM 29 Launch All Natural Double Strength Anti Inflammatory Formula 14200 1The Makers of Conquer HA 28TM 29 Launch All Natural Double Strength Anti Inflammatory Formula 14200 2
...a national reference laboratory and a worldwide le...ment. ARUP offers an extensive test menu of highly...anatomic pathology. Owned by the University of Uta...lf of the nation's university teaching hospitals a...
...a national reference laboratory and a worldwide le...ment. ARUP offers an extensive test menu of highly...anatomic pathology. Owned by the University of Uta...lf of the nation's university teaching hospitals a...
...a national reference laboratory and a worldwide le...ment. ARUP offers an extensive test menu of highly...anatomic pathology. Owned by the University of Uta...lf of the nation's university teaching hospitals a...
...a national reference laboratory and a worldwide le...ment. ARUP offers an extensive test menu of highly...anatomic pathology. Owned by the University of Uta...lf of the nation's university teaching hospitals a...
Medicine Products: